SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Butterfly Network, Inc. designs a medical imaging device that reduces the cost of real-time and three-dimensional imaging and treatment. It develops and provides a whole-body portable ultrasound scanner called the iQ Device and related hosted, web-based application, application programming interfaces and platform services, which the firm offer to physicians or other licensed health care providers. Its products include iQ+ Ultrasound, Butterfly Enterprise and iQ Vet. The company was founded by Jonathan M. Rothberg on January 25, 2011 and is headquartered in Burlington, MA.

Butterfly Network Inc - Ordinary Shares - Class A

Butterfly Network Inc

Butterfly Network is surging following record quarterly revenue and the milestone achievement of positive operating cash flow, signaling a significant transition toward profitability. Investors are actively discussing the company's shift from a pure medical device firm to a semiconductor-based AI imaging platform, with many weighing the impact of its strategic partnership with Midjourney against historical skepticism regarding share offerings and long-term cash burn.

Energy Fuels, Inc. is a mining development company, which engages in the exploration and evaluation of uranium and vanadium properties. It operates through the following segments: Uranium, Rare Earth Elements (REE), and Heavy Mineral Sands (HMS). The uranium segment engages in conventional and ISR uranium extraction, recovery and sales of uranium from mineral properties and the recycling of uranium-bearing materials generated by third parties along with the exploration, permitting and evaluation of uranium properties in the U.S. The REE segment is engaged in the company’s initiatives to progress towards full REE separation capabilities at the Mill to produce both light and heavy separated REE oxides in the coming years. The HMS segment engages in the exploration, development and recovery of HMS at the Kwale Project, Bahia Project, Vara Mada Project and the company’s equity method investments in the Donald Project JV and Tate. The company was founded by George E. L. Glasier and John David Mason on June 24, 1987 and is headquartered in Lakewood, CO.

Energy Fuels Inc

Energy Fuels is trending as investors focus on the company's strategic position at the intersection of nuclear energy and domestic rare earth supply chains, bolstered by recent government financial support and a push toward independence from foreign critical mineral sources. Community discussion centers on the potential for long-term growth driven by AI-linked power demand, while some investors urge patience as the company executes its mill retooling and finalizes key strategic partnerships.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is currently drawing significant attention as investors monitor the strong launch momentum of its Wegovy oral pill and navigate heightened competitive pressure from Eli Lilly in the GLP-1 market. The community is actively debating the stock's long-term value against its recent underperformance, with many focusing on whether expanding global access and pipeline developments can overcome concerns over pricing competition and pipeline execution.

Ardelyx, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs. Its products include IBSRELA and XPHOZAH. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

Ardelyx is attracting significant community attention due to strong IBSRELA revenue growth and speculation regarding a potential acquisition by Zydus Lifesciences. Investors are closely monitoring the stock's price action as they balance this momentum against the uncertainty surrounding the ongoing legal dispute with CMS.

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy is facing intense bearish sentiment and significant volatility as community members aggressively debate the sustainability of its debt-driven Bitcoin acquisition strategy and recent stock dilution. Investors remain deeply divided, with some highlighting the company's leverage as a potential systemic risk, while others view the current price compression as a long-term accumulation opportunity despite the ongoing downward pressure.

TOSHI

TOSHI is trending as investors speculate on a major ecosystem expansion and upcoming announcements involving new AI tools and potential burn mechanisms. The community is actively discussing the token's role on the Base chain, with many sharing bullish sentiment on its potential for a rally as they accumulate at current levels.

Sezzle, Inc. engages in the operation of a digital payment platform that enables bank-to-bank transfer of money between consumers and businesses. The company was founded by Charlie G. Youakim, Killian Brackey and Paul V. Paradis on January 4, 2016 and is headquartered in Minneapolis, MN.

Sezzle Inc.

Sezzle is seeing intense community debate as investors weigh strong earnings momentum and institutional accumulation against concerns regarding governance, legal investigations, and the broader volatility impacting the fintech sector. The conversation remains highly polarized, with many bulls anticipating a violent short squeeze driven by heavy short interest and positive product expansion, while others focus on technical pullbacks and the risks of a shifting macroeconomic landscape.

Avalanche is a high throughput smart contract blockchain&nbsp;platform. Validators secure the network through a proof-of-stake consensus protocol. It is said to be fast, low cost, and environmental friendly.

Avalanche

Avalanche is facing intense selling pressure and retail frustration as the token struggles to maintain support levels, with investors debating whether current price points represent an accumulation opportunity or the bottom of a broader downward trend. Community discussion is heavily focused on the token's lackluster performance compared to other assets, concerns over its long-term viability, and widespread skepticism regarding the impact of upcoming regulatory developments.

Roblox Corp. engages in the provision of online gaming services. Its platform consists of Roblox Client, Roblox Studio, and Roblox Cloud. Roblox Client is an application that allows users to explore 3D digital worlds. Roblox Studio is the toolset that allows developers and creators to build, publish, and operate 3D experiences and other content accessed with Roblox Client. Roblox Cloud includes the services and infrastructure that power the human co-experience platforms. The company was founded by Erik Cassel and David B. Baszucki in March 2004 and is headquartered in San Mateo, CA.

Roblox Corporation - Ordinary Shares - Class A

Roblox Corp.

Roblox is currently experiencing significant volatility following a share buyback announcement that has temporarily eased investor concerns, though the stock remains under pressure from class-action lawsuits and safety-related growth headwinds. While some investors are betting on a recovery driven by institutional support and long-term platform potential, others remain skeptical, pointing to the messy transition toward a more regulated ecosystem.

A composable native asset bridge with unified liquidity and instant guaranteed finality

Stargate

Stargate is gaining attention as community members track its price action and potential recovery from recent volatility. Discussions are heavily focused on the project's role in the DeFi ecosystem, with some investors debating entry points while others analyze its long-term utility and bridge infrastructure.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ZVRA Stock Hits Its Highest Levels In Nearly 5 Years – What’s Driving This Sharp Rally Today?

Equity

Zevra Therapeutics shares saw a series of positive brokerage actions after the company asked the U.S. Food and Drug Administration to add a new patent for its Miplyffa drug to the Orange Book.

ZVRA Stock ‘Way Undervalued’? Analyst Sees 117% Upside After Patent Extends Exclusivity Till 2041 For Sole Approved Drug

Zevra said in a statement that it has asked the U.S. Food and Drug Administration to add its new patent for its drug MIPLYFFA to its official list.


Zevra Therapeutics (ZVRA) Q1 Earnings and Revenues Surpass Estimates

Zevra Therapeutics (ZVRA) delivered earnings and revenue surprises of +184.36% and +15.51%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Ocular Therapeutix (OCUL) Reports Q1 Loss, Misses Revenue Estimates

Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of -29.46% and -15.29%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Zevra Therapeutics (ZVRA) Expected to Announce Quarterly Earnings on Wednesday

Zevra Therapeutics (NASDAQ:ZVRA) will be releasing its Q1 2026 earnings after the market closes on Wednesday, May 6. (View Earnings Report at...

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives Average Recommendation of "Moderate Buy" from Analysts

Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the nine brokerages that are currently covering the stock, Marketbeat Ratings reports. Two analysts have rated the stock with a hold rating and seven have issued a buy...

Zevra Therapeutics (NASDAQ:ZVRA) Stock Rating Upgraded by Wall Street Zen

Wall Street Zen upgraded Zevra Therapeutics from a "hold" rating to a "buy" rating in a report on Saturday...

Stratos Wealth Partners LTD. Boosts Stake in Zevra Therapeutics, Inc. $ZVRA

Stratos Wealth Partners LTD. increased its position in Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) by 78.6% in the 4th quarter, according to its most recent filing with the SEC. The fund...

JPMorgan Chase & Co. Has $4.18 Million Stock Holdings in Zevra Therapeutics, Inc. $ZVRA

JPMorgan Chase & Co. lifted its holdings in shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) by 1,458.8% in the third quarter, according to its most recent filing with the SEC. The firm...

Hennion & Walsh Asset Management Inc. Invests $1.25 Million in Zevra Therapeutics, Inc. $ZVRA

Hennion & Walsh Asset Management Inc. acquired a new stake in Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 139,591 shares of the company's sto...

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

ZVRAZevra Therapeutics Inc

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ZVRA News